TITLE

Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle

AUTHOR(S)
Mahendra Singh; Lauren Cowell; Sachiko Seo; Geraldine O'Neill; Erica Golemis
PUB. DATE
May 2007
SOURCE
Cell Biochemistry & Biophysics;May2007, Vol. 48 Issue 1, p54
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Upregulation of the scaffolding protein HEF1, also known as NEDD9 and Cas-L, has recently been identified as a pro-metastatic stimulus in a number of different solid tumors, and has also been strongly associated with pathogenesis of BCR-Abl-dependent tumors. As the evidence mounts for HEF1/NEDD9/Cas-L as a key player in metastatic cancer, it is timely to review the molecular regulation of HEF1/NEDD9/Cas-L. Most of the mortality associated with cancer arises from uncontrolled metastases, thus a better understanding of the properties of proteins specifically associated with promotion of this process may yield insights that improve cancer diagnosis and treatment. In this review, we summarize the extensive literature regarding HEF1/NEDD9/Cas-L expression and function in signaling relevant to cell attachment, migration, invasion, cell cycle, apoptosis, and oncogenic signal transduction. The complex function of HEF1/NEDD9/Cas-L revealed by this analysis leads us to propose a model in which alleviation of cell cycle checkpoints and acquired resistance to apoptosis is permissive for a HEF1/NEDD9/Cas-L-promoted pro-metastatic phenotype.
ACCESSION #
26420182

 

Related Articles

  • Optimizing Target Selection and Development Strategy in Cancer Treatment: The Next Wave. Sausville, Edward A. // Current Medicinal Chemistry - Anti-Cancer Agents;Sep2004, Vol. 4 Issue 5, p445 

    Successful cancer treatments of the future are being developed with a focus on the molecular targets underlying the pathophysiology of neoplasia. Prominent targets which have emerged are those which are mutated in the course of a cancer's development, and mediate activation or release from...

  • Apoptosis pathways in cancer and cancer therapy. Debatin, Klaus-Michael // Cancer Immunology, Immunotherapy;Mar2004, Vol. 53 Issue 3, p153 

    Activation of apoptosis pathways is a key mechanism by which cytotoxic drugs kill tumor cells. Also immunotherapy of tumors requires an apoptosis sensitive phenotype of target cells. Defects in apoptosis signalling contribute to resistance of tumors. Activation of apoptosis signalling following...

  • A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Mellor, H. R.; Ferguson, D. J. P.; Callaghan, R. // British Journal of Cancer;8/8/2005, Vol. 93 Issue 3, p302 

    The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system was developed using human colon...

  • CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. Perea, Silvio; Baladron, Idania; Garcia, Yanelda; Perera, Yasser; Lopez, Adlin; Soriano, Jorge; Batista, Noyde; Palau, Aley; Hernández, Ignacio; Farina, Hernán; Garcia, Idrian; Gonzalez, Lidia; Gil, Jeovanis; Rodriguez, Arielis; Solares, Margarita; Santana, Agueda; Cruz, Marisol; Lopez, Matilde; Valenzuela, Carmen; Reyes, Osvaldo // Molecular & Cellular Biochemistry;Oct2011, Vol. 356 Issue 1/2, p45 

    CK2 represents an oncology target scientifically validated. However, clinical research with inhibitors of the CK2-mediated phosphorylation event is still insufficient to recognize it as a clinically validated target. CIGB-300, an investigational peptide-based drug that targets the phosphoaceptor...

  • Macroautophagy as a Target of Cancer Therapy. Lorin, S�verine; Codogno, Patrice; Djavaheri-Mergny, Mojgan // Current Cancer Therapy Reviews;2007, Vol. 3 Issue 3, p199 

    Macroautophagy (hereafter referred as to autophagy) is a vacuolar lysosomal degradative pathway for cytoplasmic macromolecules and organelles. There is growing evidence that autophagy is controlled by tumor-regulating molecules, and that it is downregulated during the early stages of...

  • In Brief.  // Nature Reviews Cancer;Sep2005, Vol. 5 Issue 9, p672 

    Cites several studies regarding the treatment of cancer. Correlation of HIF overexpression with biallelic loss of fumerate hydratase in renal cancer; Ability of clusterin to inhibit apoptosis; Efficacy of atelocollagen in vivo in delivering small interfering RNA to bone-metastatic tumors.

  • PATHWAYS OF APOPTOTIC AND NON-APOPTOTIC DEATH IN TUMOUR CELLS Childs, Oliver // Nature Reviews Cancer;Aug2004, Vol. 4 Issue 8, p592 

    Defects in cell-death pathways are hallmarks of cancer. Although resistance to apoptosis is closely linked to tumorigenesis, tumour cells can still be induced to die by non-apoptotic mechanisms, such as necrosis, senescence, autophagy and mitotic catastrophe. The molecular pathways that underlie...

  • Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review. Kartachova, Marina S.; Verheij, Marcel; Hoefnagel, Cornelis A.; Van Eck, Berthe L.; Olmos, Renato A. Vald�s // Current Medical Imaging Reviews;2005, Vol. 1 Issue 3, p221 

    In vivo monitoring of apoptosis during anticancer therapy has attracted intense research interest as a potential assay to predict treatment outcome. From all apoptosis-detecting radioligands, the group of Annexin V-based tracers is currently the most widely used for real time imaging of...

  • Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol. Blackman, Ronald K.; Cheung-Ong, Kahlin; Gebbia, Marinella; Proia, David A.; He, Suqin; Kepros, Jane; Jonneaux, Aurelie; Marchetti, Philippe; Kluza, Jerome; Rao, Patricia E.; Wada, Yumiko; Giaever, Guri; Nislow, Corey // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Elesclomol is a first-in-class investigational drug currently undergoing clinical evaluation as a novel cancer therapeutic. The potent antitumor activity of the compound results from the elevation of reactive oxygen species (ROS) and oxidative stress to levels incompatible with cellular...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics